An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults

Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.

NCT Number	NCT07467707
Lead Sponsor	Bavarian Nordic Collaborators: Walter Reed Army Institute of Research (WRAIR), Congressionally Directed Medical Research Programs, United States Department of Defense, Pharmaceutical Product Development, (PPD) LLC, Armed Forces Research Institute of Medical Services, Q-square Business Intelligence, Inc.
Conditions	Chikungunya Virus
Enrollment	6,144 participants
Start Date	2026-05-26
Primary Completion	2030-05 (estimated)
Study Completion	2030-05 (estimated)
Updated on ClinicalTrials.gov	2026-06-29